Clinical Trial Update: A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas [Phase 3]

View source ↗

Summary

This document reports the completion of a Phase 3 trial comparing JCAR017 to standard of care in adults with high-risk, transplant-eligible relapsed or refracto…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• JCAR017

Snippet

Sponsor: Celgene | Conditions: Lymphoma, Non-Hodgkin | Phase 3 | Status: COMPLETED | Results posted: 2025-08-03